← Leaderboards
Maria Teresa Diaz Meco Conde
University Of Cincinnati
$9,844,614
Attributed
$11,159,526
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,159,526 · 7
By mechanism
R01$10,398,951 · 5
P30$760,575 · 2
Top collaborators
- Christian Michael Metallo6 shared
Most similar at University Of Cincinnati
Same institution · by research overlap
- Thomas Jansson$13,322,040
- Zhongyun Dong$3,681,500
Others in their field
Top investigators on “Regulation”
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
- David Heimbrook · Leidos Biomedical Research, Inc.$152,164,826
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Nevan J Krogan · University Of California, San Francisco$101,337,442
- Asimah Rafi · Technical Resources Inc$95,881,052
- Richard C Boucher · University Of North Carolina Chapel Hill$83,460,414
Research focus
RegulationMolecularIn VivoPathway InteractionsComplexMediatingCellsMalignant Neoplasm Of ProstateCancer CellMalignant NeoplasmsTumorPhenotypeEventSignal TransductionLaboratoriesProgramsGenerationsTumor ProgressionCell ProliferationMetabolicNeoplastic CellGrowthPublishingMetabolism
Grant awards (27)
Role of the CD44/Hyaluronan axis in mesenchymal prostate cancer$549,768
R01 · FY2025 · CA · contact PI
Role of the CD44/Hyaluronan axis in mesenchymal prostate cancer$522,281
R01 · FY2024 · CA · contact PI
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer$410,842
R01 · FY2024 · CA · contact PI
Role of the CD44/Hyaluronan axis in mesenchymal prostate cancer$549,768
R01 · FY2023 · CA · contact PI
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer$424,047
R01 · FY2023 · CA · contact PI
Proteomics$253,525
P30 · FY2023 · CA · contact PI
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer$424,047
R01 · FY2022 · CA · contact PI
Proteomics$253,525
P30 · FY2022 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$500,144
R01 · FY2021 · CA · contact PI
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer$432,700
R01 · FY2021 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$503,644
R01 · FY2020 · CA · contact PI
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer$450,075
R01 · FY2020 · CA · contact PI
Proteomics$253,525
P30 · FY2020 · CA · contact PI
The p62/MEKK3 complex in mTORC1 activation$432,680
R01 · FY2019 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$263,682
R01 · FY2019 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$251,866
R01 · FY2019 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$531,494
R01 · FY2018 · CA · contact PI
The p62/MEKK3 complex in mTORC1 activation$446,063
R01 · FY2018 · CA · contact PI
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer$578,994
R01 · FY2017 · CA · contact PI
The p62/MEKK3 complex in mTORC1 activation$446,063
R01 · FY2017 · CA · contact PI
The p62/MEKK3 complex in mTORC1 activation$446,063
R01 · FY2016 · CA · contact PI
The p62/MEKK3 complex in mTORC1 activation$446,063
R01 · FY2015 · CA · contact PI
The Par-4/PKCz complex in prostate cancer$368,938
R01 · FY2013 · CA · contact PI
The Par-4/PKCz complex in prostate cancer$384,435
R01 · FY2012 · CA · contact PI
The Par-4/PKCz complex in prostate cancer$384,435
R01 · FY2011 · CA · contact PI
The Par-4/PKCz complex in prostate cancer$325,775
R01 · FY2010 · CA · contact PI
The Par-4/PKCz complex in prostate cancer$325,084
R01 · FY2009 · CA · contact PI